Hye Rim Cho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8189973/publications.pdf Version: 2024-02-01



HVE RIM CHO

#	Article	IF	CITATIONS
1	Bioresorbable Electronic Stent Integrated with Therapeutic Nanoparticles for Endovascular Diseases. ACS Nano, 2015, 9, 5937-5946.	14.6	203
2	Flexible, sticky, and biodegradable wireless device for drug delivery to brain tumors. Nature Communications, 2019, 10, 5205.	12.8	148
3	Multifunctional nanoparticles as a tissue adhesive and an injectable marker for image-guided procedures. Nature Communications, 2017, 8, 15807.	12.8	67
4	Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI. Scientific Reports, 2019, 9, 11085.	3.3	48
5	Localized Delivery of Theranostic Nanoparticles and Highâ€Energy Photons using Microneedlesâ€onâ€Bioelectronics. Advanced Materials, 2021, 33, e2100425.	21.0	43
6	Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas. Oncotarget, 2015, 6, 20266-20277.	1.8	38
7	Metabolomic analysis of percutaneous fine-needle aspiration specimens of thyroid nodules: Potential application for the preoperative diagnosis of thyroid cancer. Scientific Reports, 2016, 6, 30075.	3.3	36
8	Radiogenomics Profiling for Glioblastoma-related Immune Cells Reveals CD49d Expression Correlation with MRI parameters and Prognosis. Scientific Reports, 2018, 8, 16022.	3.3	25
9	Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor. Scientific Reports, 2017, 7, 554.	3.3	24
10	Glutaminase 2 expression is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma. Scientific Reports, 2017, 7, 12221.	3.3	23
11	BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients. Scientific Reports, 2017, 7, 17740.	3.3	20
12	Sprague-Dawley rats bearing McA-RH7777 cells for study of hepatoma and transarterial chemoembolization. Anticancer Research, 2013, 33, 223-30.	1.1	14
13	Antiangiogenic Effect of Bevacizumab: Application of Arterial Spin-Labeling Perfusion MR Imaging in a Rat Glioblastoma Model. American Journal of Neuroradiology, 2016, 37, 1650-1656.	2.4	11
14	Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging. Scientific Reports, 2019, 9, 5585.	3.3	11
15	Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging. Oncotarget, 2016, 7, 69606-69615.	1.8	11
16	On the Utility of Short Echo Time (TE) Single Voxel 1H–MRS in Non–Invasive Detection of 2–Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel. PLoS ONE, 2016, 11, e0147794.	2.5	10
17	Modified Rat Hepatocellular Carcinoma Models Overexpressing Vascular Endothelial Growth Factor. Journal of Vascular and Interventional Radiology, 2018, 29, 1604-1612.	0.5	9
18	Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging. Scientific Reports, 2019, 9, 16613.	3.3	8

#	Article	IF	CITATIONS
19	Multiparametric magnetic resonance imaging features of a canine glioblastoma model. PLoS ONE, 2021, 16, e0254448.	2.5	1
20	DDIS-04. NITROXOLINE EXHIBIT ANTICANCER ACTIVITY INDUCING APOPTOSIS IN AÂTEMOZOLOMIDE-RESISTANT GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi59-vi59.	1.2	0